Presentation TCT 2015 New Data: Results of the HEAT-PPCI Platelet Substudies Presenter: Eric Boersma, E. Magnus Ohman, Rod H. Stables October 12, 2015
Presentation TCT 2015 Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin! Presenter: John A. Bittl, Robert A. Harrington, Michael S. Lee October 12, 2015
Presentation TCT 2015 Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Bivalirudin! Presenter: John A. Bittl, Robert A. Harrington, George D. Dangas October 12, 2015
Presentation TCT 2015 Is Prolonged Antithrombin Use After Primary PCI in STEMI Beneficial? Presenter: John A. Bittl, Robert A. Harrington, Mahesh Madhavan October 12, 2015
Presentation TCT 2015 Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART Presenter: John A. Bittl, Robert A. Harrington, David Erlinge October 12, 2015
Presentation TCT 2015 Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union? Presenter: John A. Bittl, Robert A. Harrington, Harvey D. White October 12, 2015
Presentation TCT 2015 What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI? Presenter: John A. Bittl, Robert A. Harrington, Jorge F. Saucedo October 12, 2015
Presentation TCT 2015 Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More Presenter: John A. Bittl, Robert A. Harrington, Philippe Gabriel Steg October 12, 2015
Presentation TCT 2015 Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results Presenter: John A. Bittl, Robert A. Harrington, Marco Valgimigli October 12, 2015
Presentation TCT 2015 Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies Focused Commentary Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, Roxana Mehran October 12, 2015
Presentation TCT 2015 Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, Marco Valgimigli October 12, 2015
Presentation TCT 2015 Debate: The Case for Short-term DAPT in Most Patients! Presenter: Regina Deible, Gennaro Giustino October 11, 2015
Presentation TCT 2015 Debate: The Case for Long-term DAPT After Stenting In Most Patients! Presenter: Regina Deible, Daniel I. Simon October 11, 2015
Presentation TCT 2015 Introduction: Why Is This Issue Important? Ischemia vs Bleeding Presenter: Regina Deible, Roxana Mehran October 11, 2015
Presentation TCT 2015 Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs! Presenter: C. Michael Gibson, Marco Valgimigli, Tullio Palmerini October 11, 2015
Presentation TCT 2015 Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered! Presenter: C. Michael Gibson, Marco Valgimigli, Ori Ben-Yehuda October 11, 2015
Presentation TCT 2015 Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)! Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman October 11, 2015
Presentation TCT 2015 Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)! Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh October 11, 2015
News Conference News TCT 2014 Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation Todd Neale October 10, 2014
News Conference News TCT 2014 Bioabsorbable Polymer DES Represent Evolution to Stenting Platform September 19, 2014